Standard BioTools
LAB
156 hedge funds and large institutions have $273M invested in Standard BioTools in 2026 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 51 increasing their positions, 45 reducing their positions, and 24 closing their positions.
13% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 45
8% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 24
5% more call options, than puts
Call options by funds: $20K | Put options by funds: $19K
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
2% less funds holding
Funds holding: 159 → 156 (-3)
2.5% less ownership
Funds ownership: 78.71% → 76.2% (-2.5%)
29% less capital invested
Capital invested by funds: $387M → $273M (-$114M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MCO
MAK Capital One
New York
|
+$8.33M |
| 2 |
LFCM
Long Focus Capital Management
San Juan,
Puerto Rico
|
+$4.04M |
| 3 |
PLC
Peapod Lane Capital
Bedford Hills,
New York
|
+$2.46M |
| 4 |
SCM
Sone Capital Management
New York
|
+$2.14M |
| 5 |
SCA
STALEY CAPITAL ADVISERS
Pittsburgh,
Pennsylvania
|
+$765K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$5.82M |
| 2 |
NAMA
Nikko Asset Management Americas
New York
|
-$4.71M |
| 3 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
-$4.71M |
| 4 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$3.93M |
| 5 |
NFGH
Nan Fung Group Holdings
Kai Tak,
Hong Kong
|
-$2.41M |
LAB Hedge Fund Activity: Q1 2026 in Review
156 of the 8,190 institutional investors tracked by Wall St. Rank reported a position in Standard BioTools (LAB) for Q1 2026, worth a combined $273M — down 29% from $387M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new LAB positions and 24 closed out — a net gain of 2 holders — while 51 added to existing stakes and 45 trimmed.
The largest buyer was MAK Capital One, adding an estimated $8.33M. The largest seller was Morgan Stanley, cutting an estimated $5.82M.
- 156 institutional investors held Standard BioTools (LAB) as of Q1 2026, down from 159 in Q4 2025.
- Funds reported $273M of Standard BioTools stock for Q1 2026, down 29% quarter-over-quarter.
- 26 funds opened new Standard BioTools positions in Q1 2026 and 24 closed out, a net change of +2 holders.
- The largest Standard BioTools buyer in Q1 2026 was MAK Capital One, an estimated $8.33M added.
- The largest Standard BioTools seller in Q1 2026 was Morgan Stanley, an estimated $5.82M sold.
Based on aggregated 13F filings for Q1 2026.